Key Points
- Halozyme director Bernadette Connaughton sold 1,625 shares on May 1 at an average price of $63.48 for total proceeds of $103,155, reducing her stake by 4.05% to 38,498 shares; the trade was executed under a pre‑arranged Rule 10b5‑1 plan and disclosed in an SEC filing.
- Halozyme missed quarterly EPS expectations (‑$0.24 vs. $1.92 expected) despite 51.6% revenue growth to $451.8M; the company has a $7.8B market cap and an average analyst rating of Hold with a $79.11 average price target.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the transaction, the director owned 38,498 shares of the company's stock, valued at $2,443,853.04. The trade was a 4.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Halozyme Therapeutics Stock Performance
HALO opened at $65.87 on Wednesday. The business's 50-day simple moving average is $66.05 and its 200 day simple moving average is $68.60. Halozyme Therapeutics, Inc. has a 52-week low of $47.50 and a 52-week high of $82.22. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. The firm has a market capitalization of $7.80 billion, a PE ratio of 26.45, a PEG ratio of 0.26 and a beta of 0.89.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $1.92 by ($2.16). The firm had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The business's revenue was up 51.6% on a year-over-year basis. During the same period last year, the business earned $1.26 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.68 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the stock. Weiss Ratings cut shares of Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a report on Tuesday, February 24th. Benchmark increased their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, February 19th. TD Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, April 29th. Finally, Wells Fargo & Company upped their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a research report on Thursday, February 19th. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of "Hold" and an average price target of $79.11.
View Our Latest Stock Report on HALO
Institutional Investors Weigh In On Halozyme Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Root Financial Partners LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $25,000. Measured Wealth Private Client Group LLC increased its position in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 124 shares during the period. Larson Financial Group LLC raised its stake in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 343 shares during the last quarter. Richardson Financial Services Inc. lifted its holdings in Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 198 shares during the period. Finally, Clearstead Advisors LLC lifted its holdings in Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company's stock valued at $37,000 after buying an additional 265 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
